To the full analysis
Fennec Pharmaceuticals stock: growth
FENCFennec Pharmaceuticals reported $44.64M in revenue for fiscal 2025, down 6.1% on the prior year, up 207.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
no data
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 204.7% | no data | no data |
| Revenue per share | 193.5% | no data | no data |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $0 | −$19.1M | −$13.48M |
| 2007 | $0 | −$13.36M | −$13.38M |
| 2008 | $0 | −$13.6M | −$10.82M |
| 2009 | $0 | −$3.01M | −$4.69M |
| 2010 | $0 | −$7.82M | −$1.93M |
| 2011 | $0 | $4.69M | −$3.23M |
| 2012 | $0 | −$5.16M | −$2.99M |
| 2013 | $0 | $1.85M | −$2.21M |
| 2014 | $0 | −$2.18M | −$1.7M |
| 2015 | $0 | −$659K | −$1.86M |
| 2016 | $0 | −$2.79M | −$2.12M |
| 2017 | $0 | −$7.05M | −$3.64M |
| 2018 | $0 | −$9.89M | −$7.83M |
| 2019 | $0 | −$13.07M | −$9.06M |
| 2020 | $170K | −$18.11M | −$15.6M |
| 2021 | $0 | −$17.35M | −$14.22M |
| 2022 | $1.54M | −$23.71M | −$18.06M |
| 2023 | $21.25M | −$16.05M | −$17.14M |
| 2024 | $47.54M | −$436K | $26.98M |
| 2025 | $44.64M | −$9.74M | −$12.47M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Undervalued since 13 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.